VYNE Therapeutics Inc (VYNE) concluded trading on Wednesday at a closing price of $1.37, with 7.46 million shares of worth about $10.22 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -42.68% during that period and on June 25, 2025 the price saw a gain of about 29.25%. Currently the company’s common shares owned by public are about 15.96M shares, out of which, 13.61M shares are available for trading.
Stock saw a price change of 49.14% in past 5 days and over the past one month there was a price change of 31.73%. Year-to-date (YTD), VYNE shares are showing a performance of -24.73% which decreased to -59.10% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.85 but also hit the highest price of $4.30 during that period. The average intraday trading volume for VYNE Therapeutics Inc shares is 271.34K. The stock is currently trading 40.95% above its 20-day simple moving average (SMA20), while that difference is up 10.83% for SMA50 and it goes to -35.18% lower than SMA200.
VYNE Therapeutics Inc (NASDAQ: VYNE) currently have 15.96M outstanding shares and institutions hold larger chunk of about 36.72% of that.
The stock has a current market capitalization of $22.83M and its 3Y-monthly beta is at 1.60. It has posted earnings per share of -$0.99 in the same period. It has Quick Ratio of 4.47 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VYNE, volatility over the week remained 13.67% while standing at 7.22% over the month.
Analysts are in expectations that VYNE Therapeutics Inc (VYNE) stock would likely to be making an EPS of 0 in the current quarter, while forecast for next quarter EPS is 0 and it is 0 for next year. For the current quarter EPS, analysts have given the company a lowest target 0 which is 0 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to drop by -13.62% while it is estimated to increase by 30.44% in next year. EPS is likely to shrink at an annualized rate of 11.71% for next 5-years, compared to annual growth of 65.87% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BTIG Research on November 18, 2024 offering a Buy rating for the stock and assigned a target price of $8 to it. Coverage by H.C. Wainwright stated VYNE Therapeutics Inc (VYNE) stock as a Buy in their note to investors on December 06, 2021, suggesting a price target of $7 for the stock.
